Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
India Pharmaceuticals
4Q CY11 Drug Master Files (DMF) filings update
Indian DMF share recovers to c46% of overall DMF filings in
4QCY11, breaking out of the recent slowing trend in filings
Large generics filings seem to be stagnating; small players
more aggressive registering an increase on yoy basis
DRRD sole DMF on Prasugrel (potential FTF), Lupin files
ophthalmic brimonidine
Indian DMFs share jumped to c46 %( +22% yoy) of overall DMF filings in 4Q CY11
after witnessing a slower rate over the last few quarters. For the full year CY2011, Indian
DMFs share in overall DMFs filings remained at similar 50% level as in CY2010 (c9%
yoy growth). China’s DMFs share of total DMFs fell from 20% in 4Q10 (18% in
CY2010) to 16% in 4Q11 and CY2011. Global DMFs increased by c10% for CY2011.
Indian large cap generics filings seem to be stagnating: Barring DRRD which
increased its filings in CY2011, most players’ filings stagnated for the year as a whole.
The number of filings from CIPLA and RBXY actually declined materially. DRRD
CY2011 filings were strong at 14; SUNP and LPC filed 6 each, CDH 8, RBXY had 2 and
CIPLA 0. TRP and IPCA each filed three DMF during the year. Small players like Hetero
Lab, Alembic were the most active with DMF filings of c12-13.
4QCY11 noteworthy filings include Dr Reddy’s sole filing on Eli Lilly’s antithrombotic
drug Effient (prasugrel), which has cUSD100mn sales in the US. This could
be a potential first-to-file opportunity given no other DMF yet (though ANDA can only be
filed after July 2013). Lupin continued its filing momentum in ophthalmics with a recent
filing on brimonidine (Alphagan-P) used in glaucoma. Among mid caps, Ipca’s filing on
primaquine, Cadila’s on erlotinib (Tarceva) and Torrent’s on darfenacin (Enablex) are
noteworthy. Other small players’ filings including Hetero’s DMF on etravirine (Intelence)
and Gland Pharma’s filing on agratroban and dalteparin (Fragmin) are the sole Indian
DMF filings and hence potentially strong. Reliance Life Science filed two niche products
including loteprednol etabonate (ophthalmic corticosteroid) and injectable nandrolone.
Among MNCs, Apotex’s filing on lansoprazole hints at a possible increase in competition
in Prevacid generic (currently four players only). Mylan’s filing on iloperidone (Fanapt) is
also worth mentioning.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
India Pharmaceuticals
4Q CY11 Drug Master Files (DMF) filings update
Indian DMF share recovers to c46% of overall DMF filings in
4QCY11, breaking out of the recent slowing trend in filings
Large generics filings seem to be stagnating; small players
more aggressive registering an increase on yoy basis
DRRD sole DMF on Prasugrel (potential FTF), Lupin files
ophthalmic brimonidine
Indian DMFs share jumped to c46 %( +22% yoy) of overall DMF filings in 4Q CY11
after witnessing a slower rate over the last few quarters. For the full year CY2011, Indian
DMFs share in overall DMFs filings remained at similar 50% level as in CY2010 (c9%
yoy growth). China’s DMFs share of total DMFs fell from 20% in 4Q10 (18% in
CY2010) to 16% in 4Q11 and CY2011. Global DMFs increased by c10% for CY2011.
Indian large cap generics filings seem to be stagnating: Barring DRRD which
increased its filings in CY2011, most players’ filings stagnated for the year as a whole.
The number of filings from CIPLA and RBXY actually declined materially. DRRD
CY2011 filings were strong at 14; SUNP and LPC filed 6 each, CDH 8, RBXY had 2 and
CIPLA 0. TRP and IPCA each filed three DMF during the year. Small players like Hetero
Lab, Alembic were the most active with DMF filings of c12-13.
4QCY11 noteworthy filings include Dr Reddy’s sole filing on Eli Lilly’s antithrombotic
drug Effient (prasugrel), which has cUSD100mn sales in the US. This could
be a potential first-to-file opportunity given no other DMF yet (though ANDA can only be
filed after July 2013). Lupin continued its filing momentum in ophthalmics with a recent
filing on brimonidine (Alphagan-P) used in glaucoma. Among mid caps, Ipca’s filing on
primaquine, Cadila’s on erlotinib (Tarceva) and Torrent’s on darfenacin (Enablex) are
noteworthy. Other small players’ filings including Hetero’s DMF on etravirine (Intelence)
and Gland Pharma’s filing on agratroban and dalteparin (Fragmin) are the sole Indian
DMF filings and hence potentially strong. Reliance Life Science filed two niche products
including loteprednol etabonate (ophthalmic corticosteroid) and injectable nandrolone.
Among MNCs, Apotex’s filing on lansoprazole hints at a possible increase in competition
in Prevacid generic (currently four players only). Mylan’s filing on iloperidone (Fanapt) is
also worth mentioning.
Share Market Investment made profitable by SHRISTOCKTIPS- Get NSE/BSE Tips via SMS and Yahoo Messenger. We give daily stock market tips for future and cash segments. As last time we said to make a sell position in NIFTY & some NIFTY selected stocksSTOCK MARKET FREE TIPSNow on Last day those who make the short position at the higher level are enjoying the handsome profits. Now the strategy you can take in the market is to wait for 1-2 days to clearing the trend again. Never make a sell position at lower level. All it stock specially TCS & INFOSYS are making a new high on daily basis. Do no make any sell position in these stocks because they are directly link to dollar. For Further update keep following our website.
ReplyDeleteRegards
SHRISTOCKTIPS TEAM